Key result
Pre-existing anticoagulant therapy in patients with proximal femur fractures was associated with a significantly higher in-house mortality rate of 7.7% compared to 3.0% in patients without anticoagulants.
Why the study?
Anticoagulants pose a challenge for necessary early surgery in proximal femur fracture patients presenting with increasing comorbidities, prompting investigation into their influence on in-house mortality.
Does pre-existing anticoagulant therapy increase in-house mortality in patients undergoing surgical treatment for proximal femoral fractures?
Cohort (n=1,933)
No
Does pre-existing anticoagulant therapy increase in-house mortality in patients undergoing surgical treatment for proximal femoral fractures?
Absolute Event Rate: 7.7% vs 3%
p-value: p=<0.00
Pre-existing anticoagulant therapy in patients with proximal femur fractures is associated with delayed surgery and increased in-house mortality, emphasizing the importance of optimizing patients for surgery within a 48-hour window.
Warrants heightened perioperative vigilance in anticoagulated proximal femur fracture patients; leaves open causality and requires prospective confirmation.
PURPOSE: The prevalence of proximal femur fractures is increasing with rising population age. Patients are presenting with more comorbidities. Anticoagulants create a challenge for the necessary early surgical procedure (osteosynthesis or arthroplasty). Our aim was to investigate the influence of anticoagulants on in-house mortality after surgical treatment of proximal femoral fractures. METHODS: A retrospective single-centre study was conducted including 1933 patients with an average age of 79.8 years treated operatively for a proximal femoral fracture between January 2016 and June 2020. One treatment protocol was performed based on type of anticoagulant, surgery, and renal function. Patient data, surgical procedure, time to surgery, complications and mortality were assessed. RESULTS: On average, patients with anticoagulants had a delay to surgery of 41.37 hours vs 22.1 hours for patients without (p < 0.000). Anticoagulants were associated with the occurrence of complications. The total complication rate was 22.4%. Patients with complications showed a prolonged time to surgery in comparison to those without (28.9 h vs 24.9 h; p < 0.00). In-house mortality rate was 4% and twice as high for patients on anticoagulants (7.7%; p < 0.00). Whilst there was no significant difference in the mortality rate between surgery within 24 and 48 hours (2.9% vs. 3.8%; p < 0.535), there was a significant increase in mortality of patients waiting more than 48 hours (9.8%; p < 0.001). CONCLUSIONS: Pre-existing anticoagulant therapy in patients with proximal femur fractures is associated with a higher mortality rate, risk of complications and prolonged hospital stay. Further influential factors are age, gender, BMI and time to surgery.
No takes yet. Share an insight, caveat, or question.
Fenwick et al. (2022) conducted a cohort in Proximal femoral fracture (n=1,933). Anticoagulant therapy vs. No anticoagulants was evaluated on In-house mortality (p=<0.00). Pre-existing anticoagulant therapy in patients with proximal femur fractures was associated with a significantly higher in-house mortality rate of 7.7% compared to 3.0% in patients without anticoagulants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: